DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

MLA

David J. Figueroa, et al. “DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma.” Blood, vol. 138, Nov. 2021, p. 2738. EBSCOhost, https://doi.org/10.1182/blood-2021-153315.

APA

David J. Figueroa, Danae Williams, Saad Z. Usmani, Aránzazu Alonso Alonso, Anne Yeakey, Chang-Ki Min, Brandon E. Kremer, Ira Gupta, Wojciech Janowski, Morrys C. Kaisermann, Hang Quach, Geraldine Ferron-Brady, Lukasz M. Mis, Youngil Koh, Xiaoou L. Zhou, & Andreas Guenther. (2021). DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Blood, 138, 2738. https://doi.org/10.1182/blood-2021-153315

Chicago

David J. Figueroa, Danae Williams, Saad Z. Usmani, Aránzazu Alonso Alonso, Anne Yeakey, Chang-Ki Min, Brandon E. Kremer, et al. 2021. “DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma.” Blood 138 (November): 2738. doi:10.1182/blood-2021-153315.